Annual report pursuant to Section 13 and 15(d)

Nature of Business and Basis of Presentation

v2.4.0.6
Nature of Business and Basis of Presentation
 12 Months Ended
Dec. 31, 2012
Nature of Business and Basis of Presentation [Abstract]  
NATURE OF BUSINESS AND BASIS OF PRESENTATION

1. NATURE OF BUSINESS AND BASIS OF PRESENTATION

OncoGenex Pharmaceuticals, Inc. (the “Company” or “OncoGenex”) is committed to the development and commercialization of new therapies that address treatment resistance in cancer patients. The Company was incorporated in the state of Delaware and is headquartered in Bothell, Washington and has a subsidiary in Vancouver, British Columbia.

Basis of Presentation

The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States. The consolidated financial statements include the accounts of OncoGenex Pharmaceuticals, Inc. and its wholly owned subsidiary OncoGenex Technologies Inc.

Liquidity

The Company has historically experienced recurring losses from operations that have generated an accumulated deficit of $101.8 million through December 31, 2012. At December 31, 2012, the Company had cash, cash equivalents and short-term investments of $75.4 million.